Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination With Gemcitabine and Cisplatin in the First-Line Treatment of Patients With Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT01763788 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01763788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01763788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination With Gemcitabine and Cisplatin in the First-Line Treatment of Patients With Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Completed
Start date
May 7, 2013
Completion date
October 17, 2018
Enrollment
192 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

squamous non-small cell lung cancer